Atara Biotherapeutics to Participate at Three Upcoming Investor Conferences

Author's Avatar
Nov 08, 2021

Atara+Biotherapeutics%2C+Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer of Atara, will participate at three upcoming virtual conferences.